NEUROPATHOLOGY
Glioma tumour biology: from histopathology to molecular diagnostics
The integration of molecular pathology into routine diagnostic practice has transformed the classification, diagnosis and management of neoplastic disease, a prime example of which can be found in neuropathology. Here, Eleanor Crossland explores the biological complexity of the glioma tumour microenvironment and examines the role of immune cells, molecular biomarkers and genetic testing in neuropathology.
The human brain is one of the most complex biological structures. Consequently, diseases affecting the central nervous system present some of the greatest challenges in modern medicine. Among these conditions, gliomas remain particularly significant due to their aggressive nature, diagnostic complexity and poor clinical outcomes. Despite advances in surgery, radiotherapy and systemic therapies, gliomas continue to account for substantial morbidity and mortality worldwide.1 Historically, glioma classification
relied heavily on microscopic examination of tissue architecture and cellular morphology. Histopathological features such as cellular atypia, mitotic activity, necrosis and microvascular proliferation formed the foundation of tumour grading. While these morphological characteristics remain essential, advances in molecular pathology have demonstrated that tumours with similar microscopical appearance may possess markedly different biological behaviour and clinical outcomes.2 Publication of the fifth edition of
the World Health Organization (WHO) Classification of Tumors of the Central Nervous System (WHO CNS5) is a major milestone in neuropathology. Molecular alterations now form part of the diagnostic criteria, rather than acting as supplementary information.3
Glioblastoma, one of the most aggressive and therapeutically challenging primary brain tumours (haematoxylin and eosin [H&E] stain).
Biomarkers including IDH mutation status, ATRX loss, 1p/19q codeletion, TERT promoter mutations and CDKN2A/B deletions have become integral to diagnosis, prognostication and treatment planning. Histopathological assessment is now interpreted
alongside immunohistochemistry (IHC) findings and genomic data to produce comprehensive integrated reports. Understanding molecular pathways, genomic alterations and biomarker significance has become an essential component of professional practice.
August 2026
WWW.PATHOLOGYINPRACTICE.COM 27
KGH (assumed) / CC BY-SA 3.0 / Wikimedia Commons
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
